Hypercalcemia in idiopathic myelofibrosis: Modulation of calcium and collagen homeostasis by 1,25‐dihydroxyvitamin D3 | Zendy

Voss A. | Zendy; Schmidt K. | Zendy; Hasselbalch H. | Zendy; Junker P. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Hypercalcemia in idiopathic myelofibrosis: Modulation of calcium and collagen homeostasis by 1,25‐dihydroxyvitamin D3

Author(s) -

Voss A.,

Schmidt K.,

Hasselbalch H.,

Junker P.

Publication year - 1992

Publication title -

american journal of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.456

H-Index - 105

eISSN - 1096-8652

pISSN - 0361-8609

DOI - 10.1002/ajh.2830390316

Subject(s) - myelofibrosis , endocrinology , medicine , procollagen peptidase , calcium , calcium metabolism , bone marrow , fibrosis , vitamin d and neurology , osteomalacia , in vivo , calcitriol , homeostasis , biology , microbiology and biotechnology

A case of idiopathic myelofibrosis (IMF) presenting with hypercalcemia and hypercalcitriolemia is reported. It is proposed that ectopic production of the active vitamin D metabolite related to ongoing clonal expansion in the bone marrow accounts for the hypercalcemic state. Consistently low levels of circulating type I procollagen propeptide (PICP) and lack of progression of the bone marrow fibrosis during almost 6 months of follow‐up point to an in vivo inhibition of type I collagen synthesis by 1,25‐dihydroxyvitamin D3.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research